Overview
Quick answer
If you are searching perimenopause after irregular periods, hot flushes, wrecked sleep, or a brain-fog month, the first job is to stop waiting for a blood test to confirm the name. The Australasian Menopause Society diagnoses perimenopause clinically: new vasomotor or other symptoms plus a change in bleeding. Healthdirect (last reviewed November 2025) says the same. Tests are usually not needed to confirm it.
A single follicle-stimulating hormone (FSH) or oestradiol result is not a reliable indicator of perimenopause. Those hormones fluctuate from day to day, and oestradiol can briefly run high, not only low. AMS tells clinicians not to measure FSH, oestradiol, luteinising hormone (LH), anti-Mullerian hormone (AMH), or testosterone in a woman with typical symptoms at the usual age (over 45), because the result will not change management.
Blood still has a job. It filters the lookalikes (thyroid disease, iron deficiency, anaemia) and sets a midlife baseline for lipids and glucose, which do change in this decade. That is the useful panel. It is not a menopause diagnosis.
Overview
Key takeaways
Perimenopause is a clinical diagnosis in women over 45: symptoms and cycle change, not a lab flag. Menopause is dated 12 months after the final period. The average age in Australian women is 51 (usual range 45 to 55).
A single FSH or oestradiol pair cannot stage you. Levels swing daily. AMS and the 2023 Practitioner's Toolkit treat those assays as unnecessary at the usual age.
Oestradiol can briefly be higher than normal in perimenopause. Breast tenderness and heavy bleeding can be oestrogen excess, not proof you are "not there yet."
FSH testing is for women under 45, after hysterectomy when cycles cannot be read, or when another illness is on the table. Premature ovarian insufficiency (before 40) needs elevated FSH on two occasions, 4 to 6 weeks apart.
AMH is not a menopause test. RANZCOG does not recommend it to predict or diagnose menopause. AMS lists it in the "do not measure" set over 45.
The useful bloods are TSH, a full blood count and ferritin, fasting glucose or HbA1c, and a lipid profile. Those catch lookalikes and the midlife risk shift.
Do not read hormone bloods on menopausal hormone therapy or the combined pill. Symptoms, not biochemistry, guide that therapy.
A membership panel does not diagnose perimenopause. It can track the markers that still move.
The frame
Diagnosis is clinical
Most people arrive here because a webpage, a pharmacy kit, or a well-meaning relative said "get your hormones tested." That is the wrong first move at the usual age, and it is why so many printouts look confusing.
The AMS line, not a wellness slogan
The Australasian Menopause Society information sheet Diagnosing menopause opens with this: perimenopause is usually diagnosed clinically on new-onset vasomotor or other symptoms and a change in menstrual bleeding. Menopause is diagnosed 12 months after the final menstrual period. Measuring oestradiol or FSH is generally not indicated because of marked daily fluctuations.
Healthdirect says the same thing
Healthdirect (last reviewed November 2025) writes that tests are usually not needed to confirm perimenopause, and that the diagnosis is based on age, symptoms, and period changes. An FSH test may help if you are under 45. That is a government consumer page restating college practice, not a clinic upsell.
51 is the average, not a deadline
AMS: the average age of menopause in Australian women is 51 years, with a usual range of 45 to 55. Perimenopause lasts about 4 to 8 years (Healthdirect and AMS). Some women have symptoms for 5 to 10 years before the final period. None of those figures dates your last bleed.
STRAW+10, the international staging system AMS uses, starts perimenopause when consecutive cycles differ in length by seven or more days, and ends it 12 months after the last period. If you have a levonorgestrel IUD, other hormonal contraception, an endometrial ablation, or a hysterectomy, those cycle rules do not apply. Symptoms carry the diagnosis.
Mechanism
Why the hormones swing
The reason a Tuesday FSH can disagree with a Friday FSH is not lab error. It is how the remaining ovary and the pituitary talk to each other while the follicle pool is running down.
Fewer follicles, less inhibin B, a swinging FSH
Granulosa cells in growing follicles make inhibin B, which holds pituitary FSH down. As the recruitable follicle pool shrinks, inhibin B falls and FSH rises, but not as a smooth ramp. Remaining follicles still respond, so FSH can look postmenopausal one week and ordinary the next. Burger (2011), cited by AMS, called this the unpredictable endocrinology of the transition. That is why one elevated FSH is not a stage.
Oestradiol can spike before it falls
AMS is explicit: at a time when the body is running out of oestrogen, brief periods of high oestradiol still happen. That can show up as breast tenderness, heavy bleeding, or migraine. A "high oestradiol" on a perimenopause form is compatible with the diagnosis. It is not proof you are fine. Eventually deficiency symptoms predominate.
Hot flushes are a narrower thermostat, not "just stress"
A hot flush is a sudden sense of heat with skin vasodilation and a drop in core temperature. AMS describes a narrower thermoneutral zone in oestrogen deficiency: a small rise in core temperature feels extreme, and the body dumps heat. KNDy neurons in the hypothalamus hypertrophy after menopause and express neurokinin B, which can induce flushes (Rance et al., cited by AMS). About 75% of postmenopausal women report vasomotor symptoms; a quarter of those are severely affected. The median duration in the SWAN cohort was 7 years (Avis et al., 2015).
The midlife metabolic and bone shift is real
Falling oestrogen, with ageing, is associated with more visceral fat, adverse lipids, higher insulin resistance, and faster bone resorption, because oestrogen limits osteoclast activity. AMS and the American Heart Association scientific statement on the menopause transition treat this as a cardiovascular-risk window, not a cosmetic one. That is why lipids and glucose belong on the form even when FSH does not.
About 20% of women report no menopausal symptoms (AMS). The absence of flushes does not mean the metabolic or bone shift is absent. The presence of flushes does not mean a hormone panel will explain them.
The panel
What blood tests actually do
Blood has three honest jobs in this decade: exclude the conditions that mimic the story, document midlife cardiometabolic risk, and, in a minority, support a diagnosis of early menopause or premature ovarian insufficiency. It does not date the final period.
Lookalikes: thyroid, iron, anaemia
AMS says depression, anaemia, and thyroid disorders are the common concurrent conditions. Unstable diabetes and hyperthyroidism can cause flushes. A blood count, ferritin, and TSH usually sort those. Hair loss in this decade is as often iron or thyroid as it is "hormones." That is a filter, not a menopause test.
Midlife risk: lipids and glucose
The AMS perimenopause sheet lists acceleration of bone loss, central adiposity, adverse lipid changes, and altered glucose metabolism as the chronic-disease shift. The 2023 Practitioner's Toolkit (Davis et al.), endorsed by AMS, the Endocrine Society of Australia, and Jean Hailes, treats a midlife health assessment as part of the consult. Fasting lipids and a glucose test belong here. They are not FSH by another name.
FSH and oestradiol, only when the age or the story is atypical
Measure them if you are under 45 with menopausal symptoms, if cycles cannot be read (hysterectomy, ablation, some contraception), or if another pituitary or ovarian problem is plausible. The 2023 Toolkit's diagnostic set is FSH, oestradiol, AMH, and inhibin B, only if the presentation is atypical or you are under 45. LH and progesterone are not part of that set, and the Toolkit itself notes AMH still lacks accuracy for predicting menopause before the average age of 48.
Androgens are not a routine peri-menopause screen
AMS calls a routine androgen profile on every peri-menopausal woman unnecessary and costly. Testosterone can still matter for libido, bone, and a PCOS overlap. That is a targeted add, not a default. The testosterone guide covers the assay. This page does not rebuild it.
Hormone bloods on menopausal hormone therapy or the combined oral contraceptive are especially unhelpful. AMS: treat the symptoms, not the biochemistry. The assays are suppressed or distorted by the medicine you are already taking.
Reading your results
How to read an Australian printout
If FSH and oestradiol were ordered anyway, the printout is still readable. Australian labs print method- and cycle-dependent intervals. Match the row and the printed interval, not a remembered US pg/mL page.
"FSH" or "Follicle stimulating hormone"
In IU/L, sometimes printed as U/L. RCPA (last reviewed 2 January 2024) says the interval is method dependent and related to the menstrual cycle. The Manual's worked example is 1.0 to 8.0 U/L in females and greater than 18.0 U/L after menopause. A result above 18 on a still-cycling woman is a clue, not a stage. A result of 6 does not rule perimenopause out.
"Oestradiol", "Estradiol", or "E2"
In pmol/L on Australian reports. RCPA (last reviewed 2 January 2024): early follicular 100 to 200, preovulatory 500 to 1700, luteal 500 to 900, postmenopausal 70 to 200 pmol/L. Those are method-dependent examples. A mid-range follicular number in a 48-year-old with flushes does not postpone the diagnosis. Do not convert a US pg/mL blog against this row without checking the unit.
"LH" and "Progesterone"
LH in IU/L, progesterone in nmol/L. Neither is part of the 2023 Toolkit's diagnostic set for menopause status. Progesterone can confirm that a particular cycle ovulated. It cannot tell you how many cycles you have left.
"AMH" or "Anti-Mullerian hormone"
In pmol/L. Made by small ovarian follicles and used for ovarian reserve and, in adults, as a PCOS morphology stand-in. RANZCOG: AMH is not currently recommended to predict or diagnose menopause. A falling AMH is not a date for your last period.
"TSH"
In mIU/L. This is the lookalike row. Free T4 is added when TSH is abnormal. Thyroid disease can copy fatigue, weight change, hair change, and, when overactive, flushes. Read it as a differential, not as a menopause hormone.
"Ferritin" and the full blood count
Ferritin in µg/L, haemoglobin in g/L. Heavy perimenopausal bleeding is a common way to empty iron stores. Australian practice treats ferritin under 30 µg/L as depleted in a well adult. A normal haemoglobin does not rule that out. See the ferritin guide for the Australian versus WHO cut-off.
Cycle day still matters for FSH, LH, oestradiol, and progesterone if you are bleeding. AMH and TSH do not need cycle timing. If the request form does not say which day you were on, the hormone rows are harder to read, not more diagnostic.
The useful set
What to test anyway
This is the section most Australian consumer pages skip. They argue about whether to order FSH. The better question is which tests change what you do next even when the diagnosis is already clinical.
Thyroid, because the symptoms overlap
Fatigue, weight change, hair change, low mood, and heat intolerance sit on both lists. Walsh (MJA 2016) put overt hypothyroidism at about 0.5% of Australians and subclinical at about 5%. TSH is the first-line test. The thyroid guide covers the assay. Do not treat a normal TSH as proof the flushes are "just stress."
Iron, because the bleeding often changes
Heavier or more frequent periods are common in the transition. Iron deficiency without anaemia is a recognised cause of fatigue and hair shedding. The fatigue and ferritin guides already walk the Australian under-30 µg/L threshold. Order the iron studies for the bleeding, not to diagnose perimenopause.
Lipids and ApoB, because risk moves
Adverse lipid changes are part of the AMS midlife list. Australian reports print mmol/L. The 2023 Australian cardiovascular-risk guideline treats from five-year risk, not from a single LDL target. ApoB counts atherogenic particles when LDL-C is a weak story. The high-cholesterol and ApoB guides cover the printout. This page does not rebuild them.
Glucose and HbA1c, because insulin resistance can rise
Altered glucose metabolism is on the same AMS list. HbA1c does not need fasting and is reported in mmol/mol. It can still be in the reference interval while fasting insulin is already moving. The HbA1c and fasting-insulin guides cover those assays. Neither diagnoses perimenopause.
Bone density is imaging, not a blood test. A hormone panel does not replace a fracture-risk conversation. Cancer screening (breast, cervix, bowel) is a separate midlife checklist and is not on a membership pathology form.
For the assays themselves, see the thyroid guide, the ferritin guide, the high-cholesterol guide, and the HbA1c guide. For how to read oestradiol, FSH, LH and progesterone on an Australian printout, see the oestradiol and female hormone panel guide.
When FSH earns its keep
Under 45, POI, and contraception
The "do not test FSH" rule is an over-45 rule. Under 45, blood earns its keep.
Early menopause is 40 to 45. POI is before 40.
AMS and RANZCOG use those age cuts. Premature ovarian insufficiency is a pathological condition, not an early version of a normal transition. It carries higher later risk for bone, heart, and, in some series, cognition. That is why the assays are indicated, and why the result is repeated.
Two FSH results, 4 to 6 weeks apart
AMS: measure FSH in women under 40 and in women 40 to 45 with menopausal symptoms. Premature menopause is diagnosed by elevated FSH on two occasions, 4 to 6 weeks apart. This page does not invent a single IU/L cut-off. Use the lab interval and a clinician. One high number is not enough.
About 1% of women have spontaneous POI
AMS cites about 1% for spontaneous premature menopause, and around another 6% from surgery, chemotherapy, or radiation. Those are epidemiology, not your result. Family history, autoimmune disease, and cancer treatment change the prior. They do not replace the two FSH draws.
Contraception continues through the transition
You can still ovulate. AMS: contraception for 2 years after the final period if you are under 50, and for 1 year if you are 50 or over. On progestogen-only methods, amenorrhoea can hide the final-period date. In women 50 or older, AMS/FSRH use a single FSH of 30 IU/L or above as a contraception-stopping rule, then 12 more months. That is a contraception rule, not a perimenopause diagnosis.
Surgical removal of both ovaries is menopause without a perimenopause. You do not need FSH to name that. You may still want the lookalike and midlife-risk set.
Limits
What blood tests cannot show
A printout reports circulating hormones and, if you add them, iron, thyroid, lipids, and glucose. It does not watch you sleep, date your last period, or choose a therapy.
Whether you are "in" perimenopause
Over 45 with typical symptoms and cycle change, the diagnosis is already clinical. A reassuring FSH does not undo it. A high FSH does not prove it. Under 45, two timed FSH results can support early menopause or POI. One draw cannot.
How long it will last, or when the final period is
AMS: there is no reliable way to predict duration. Vasomotor symptoms may settle in 2 to 5 years; the SWAN median was 7; 10% to 20% still have symptoms at 12 years. AMH does not give you the date. RANZCOG rejects it for that job.
Whether you need menopausal hormone therapy
Indications are clinical: troublesome symptoms, and a risk-benefit conversation. AMS is explicit that you treat symptoms, not biochemistry, and that hormone levels on MHT are not the guide. This page does not recommend, dose, or sell MHT.
Mood, sleep, cognition, and bone
Low mood in this decade needs a proper assessment; AMS treats perimenopause as a window of vulnerability, especially with a past hormone-related mood history. "Brain fog" is a description. Cognitive testing is not indicated unless symptoms are progressive and interfere with work or relationships (AMS cognition sheet). Bone density is a scan. None of those is an FSH diagnosis.
Very heavy bleeding, bleeding between periods, bleeding after sex, or any bleed after 12 months without a period is a GP visit, not a membership question. AMS and Healthdirect both flag those as reasons to investigate, not to order another FSH.
How to order
How Australians get these tests
| Approach | Best for | Typical cost | What it covers |
|---|---|---|---|
| GP-ordered lookalike and midlife set | Typical symptoms over 45, or anyone whose fatigue, flushes, or heavy bleeding could be thyroid, iron, or glucose | Often bulk-billed or low gap when clinically indicated. TSH, FBE, ferritin, glucose or HbA1c, and a standard lipid panel are usual Medicare pathology when the history supports them. | TSH, full blood count, ferritin, fasting glucose or HbA1c, and lipids. This is the useful panel at the usual age. It is not a menopause diagnosis. |
| GP-ordered FSH and oestradiol | Under 45 with menopausal symptoms, cycles that cannot be read, or a genuinely uncertain differential | MBS item 66695 covers one hormone or binding-protein assay (schedule fee $30.50), including FSH, LH, oestradiol, progesterone, testosterone, and SHBG. Extra assays on the same request use the related P2 items. | FSH and oestradiol, repeated 4 to 6 weeks later if POI or early menopause is the question. Not AMH. Not a reason to test at 51 with classic flushes. |
| GP-ordered private AMH | Ovarian-reserve or adult PCOS morphology questions, not menopause staging | Private. RCPA classifies AMH as non-MBS-rebatable. Ask the lab. Do not use a US price list. | AMH in pmol/L. RANZCOG does not recommend it to predict or diagnose menopause. |
| Membership platforms (e.g. Hemexa) | The lookalike set, the female hormone set, and a lipid and glucose trend on one record | ~$1,199/year (full membership) | TSH, ferritin and a full blood count, oestradiol, FSH, LH, and progesterone on the female annual baseline, plus fasting insulin, fasting glucose, HbA1c, and lipids among 76–80 signature markers. AMH and prolactin are add-ons. A membership does not diagnose perimenopause. |
Pathology in Australia requires an authorised request from a registered medical practitioner. Collection for Hemexa members is through Healius Pathology, with regional brands that differ by state. A request form is not a diagnosis, and a membership is not a substitute for a GP visit about heavy bleeding, a suspected POI, or a first period-free year.
FAQ
Frequently asked questions
- Can a blood test diagnose perimenopause?
- Not at the usual age. AMS and Healthdirect treat perimenopause as a clinical diagnosis: symptoms and cycle change in women over 45. A single FSH or oestradiol result fluctuates day to day and is not a reliable indicator. Blood is useful under 45, after hysterectomy, or to exclude thyroid disease, iron deficiency, and other lookalikes.
- My FSH is normal. Does that mean I am not perimenopausal?
- No. FSH can sit inside the printed interval one week and look postmenopausal the next. AMS tells clinicians not to use that assay to diagnose the transition over 45, because the result will not change management. The history still counts.
- My oestradiol is high. Can I still be in perimenopause?
- Yes. AMS notes that oestradiol can briefly be higher than normal during the transition, with symptoms of oestrogen excess such as breast tenderness. A high row does not postpone the diagnosis and does not, on its own, mean you need progesterone from a webpage.
- Should I get an AMH test to see how close I am to menopause?
- No. RANZCOG does not currently recommend AMH to predict or diagnose menopause. AMS lists AMH in the set not to measure over 45 for this purpose. AMH has other jobs, including adult PCOS morphology and ovarian-reserve counselling. Those are different questions.
- I am 42 with irregular cycles and flushes. What should be tested?
- Under 45, FSH and oestradiol are indicated, and AMS wants a repeat FSH 4 to 6 weeks later if early menopause or POI is the question. Also test TSH, a blood count and ferritin, and consider glucose and lipids. Do not stop contraception because a single FSH looked high.
- Can I be tested while I am on the pill or on MHT?
- You can have TSH, ferritin, lipids, and glucose. Hormone levels used to "diagnose menopause" or to titrate MHT are not useful on those medicines. AMS: symptoms, not blood levels, guide therapy. Do not stop contraception or MHT because a webpage asked for a cleaner FSH.
- How much do perimenopause blood tests cost in Australia?
- TSH, FBE, ferritin, glucose or HbA1c, and a standard lipid panel are usually Medicare-rebated when a GP orders them for a clinical reason. FSH, oestradiol, LH, progesterone, testosterone, and SHBG sit on MBS item 66695 (schedule fee $30.50 for one assay) and the related P2 items. AMH is non-MBS-rebatable. Memberships that include the hormone and metabolic markers on a panel of 76–80 signature markers start around AU$1,199 per year.
- Does Hemexa diagnose perimenopause?
- No. Diagnosis is clinical. Hemexa's female annual baseline includes oestradiol, FSH, LH, and progesterone, among 76–80 signature markers, plus TSH, ferritin, a full blood count, lipids, fasting insulin, fasting glucose, and HbA1c. The metabolic markers that are biannual repeat on the included six-month retest. AMH and prolactin are add-ons. Collection is through Healius Pathology. A membership does not replace a GP visit about bleeding, POI, or whether MHT is appropriate.
How Hemexa fits
How Hemexa can help
Perimenopause is diagnosed in a clinic. The useful product move is to put the lookalike markers, the female hormone set, and the midlife metabolic markers on one record, then watch the ones that move.
Female hormones on the female baseline
Oestradiol, FSH, LH, and progesterone are the four female-only baseline markers. They describe the cycle you were in and help when the story is under 45 or otherwise atypical. They are not themselves a perimenopause diagnosis. AMH and prolactin are add-ons, not silent inclusions.
Lookalikes on the same baseline
TSH, ferritin, iron studies, and a full blood count sit on the annual baseline. That is the AMS differential set (thyroid, anaemia, iron), not a claim that the panel names the transition.
Metabolic markers twice a year
Fasting insulin, fasting glucose, and HbA1c sit on the annual baseline and the included six-month retest. Lipids and ApoB are on the same preventative panel. That is Hemexa's cadence for the midlife risk shift AMS describes, not a menopause score.
Dashboard bands are Hemexa policy
The member app applies Hemexa preventative bands to these markers. Hormone policy rows in the live database conflict across cycle phases and several cite a single-state lab brand, so this page does not quote a single Hemexa "optimal" FSH or oestradiol. Use the interval on your own report, then the dashboard as company policy, not as an AMS diagnostic rule.
Collection through Healius Pathology
Healius Pathology is Hemexa's collection partner, with regional brands that differ by state. Results from other Australian labs can be imported after your first baseline. The partner is the network, not one state brand.
Sources
References
Australasian Menopause Society. Diagnosing menopause (information sheet). View source ↗
Australasian Menopause Society. What is menopause? (information sheet). View source ↗
Healthdirect Australia. Perimenopause (last reviewed November 2025). View source ↗
Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Managing menopausal symptoms. View source ↗
Davis, S. R., et al. (2023). The 2023 Practitioner's Toolkit for Managing Menopause. Climacteric, 26(6), 517-536. View source ↗